Cargando…
Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing
Dynamin 2 (DNM2) is a large GTPase, ubiquitously expressed, involved in membrane trafficking and regulation of actin and microtubule cytoskeletons. DNM2 mutations cause autosomal dominant centronuclear myopathy which is a rare congenital myopathy characterized by skeletal muscle weakness and histopa...
Autores principales: | Trochet, Delphine, Prudhon, Bernard, Jollet, Arnaud, Lorain, Stéphanie, Bitoun, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056991/ https://www.ncbi.nlm.nih.gov/pubmed/27623444 http://dx.doi.org/10.1038/mtna.2016.67 |
Ejemplares similares
-
Allele‐specific silencing therapy for Dynamin 2‐related dominant centronuclear myopathy
por: Trochet, Delphine, et al.
Publicado: (2017) -
Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy
por: Azibani, Feriel, et al.
Publicado: (2018) -
Repair of Rhodopsin mRNA by Spliceosome-Mediated RNA Trans-Splicing: A New Approach for Autosomal Dominant Retinitis Pigmentosa
por: Berger, Adeline, et al.
Publicado: (2015) -
Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations
por: Dudhal, Swati, et al.
Publicado: (2022) -
A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target
por: Trochet, Delphine, et al.
Publicado: (2021)